Home / News / Events / Events detail
Recently, Dr. Jiang Yue, the investment manager at Viva BioInnovator, was invited to the 15th session of Viva's live broadcast. He provided industry analysis and insights on the development, challenges, and case studies of non-anticancer XDC drugs. Regarding the topic of "Trends in the Development of Non-anticancer XDC Drugs," he gave his predictions from an investor's perspective. On one hand, he believed that there are products or tracks that major pharmaceutical companies and multinational corporations cannot afford to abandon. This may present potential opportunities for mergers and acquisitions, licensing, co-development, and more. On the other hand, he highlighted the combination of new disease biology understanding with unmet clinical needs as another important aspect to consider. He also introduced the contributions made by Viva in ADC drug development. Viva Biotech possesses extensive experience in ADC linker and payload/warhead synthesis, as well as offering ADC antibody drug discovery services that cover the entire process from target identification to candidate antibody molecule discovery. Viva has successfully assisted clients in completing multiple ADC Functional Assays.
To watch the full video playback, please visit BiliBili.
Copyright © Viva Biotech All Rights Reserved. 沪ICP备19036061号
- About Us
-
CRO Services
BackCRO ServicesDiscovery Biology Services
- CDMO Services
- EFS Business
- News
- Careers
- Investor Relations
- Contact Us